title: Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
abstract: Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafenib in patients with hormone-refractory prostate cancer indicate that, despite a relatively short progression-free survival, the treatment may be associated with good outcomes in terms of overall survival and maintenance of a good quality of life. The study presents the authors' critical opinions and observations about the usefulness of sorafenib in patients with prostate cancer.
authors.affiliation: Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Zaborowska
authors.forename: Sebastian
authors.initials: S
authors.lastname: Szmit
authors.forename: Cezary
authors.initials: C
authors.lastname: Szczylik